Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial [Yahoo! Finance]
Agilent Technologies, Inc. (A)
Last agilent technologies, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.agilent.com
Company Research
Source: Yahoo! Finance
biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, and Agilent Technologies, announce a collaboration to develop a Claudin18.2 (CLDN18.2) companion diagnostic to support TranStar301 global Phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy as first-line treatment in patients with CLDN18.2 expressing locally advanced or metastatic gastric or gastroesophageal (G/GEJ) adenocarcinoma. Transcenta has developed a mouse anti-CLDN18.2 monoclonal antibody, clone 14G11 which specifically binds to CLDN18.2 but not CLDN18.1. This antibody, generated against a linear epitope located on the extracellular domain of loop 1, has a binding site that overlaps with the binding site of therapeutic antibody Osemitamab (TST001). Transcenta has been collaborating with Agilent, a world leader in CDx development, to further develop this antibody for use in a companion d
Show less
Read more
Impact Snapshot
Event Time:
A
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
A alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
A alerts
High impacting Agilent Technologies, Inc. news events
Weekly update
A roundup of the hottest topics
A
News
- Will Agilent (A) Beat Estimates Again in Its Next Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Agilent to Announce Second-Quarter Fiscal Year 2024 Financial Results May 29Business Wire
- Why Agilent Technologies (A) is a Top Stock for the Long-Term [Yahoo! Finance]Yahoo! Finance
- Insiders At Agilent Technologies Sold US$4.4m In Stock, Alluding To Potential Weakness [Yahoo! Finance]Yahoo! Finance
- Padraig McDonnell Assumes Agilent CEO Role [Yahoo! Finance]Yahoo! Finance
A
Earnings
- 2/27/24 - Beat
A
Sec Filings
- 5/1/24 - Form 8-K
- 4/10/24 - Form SC
- 3/27/24 - Form 4
- A's page on the SEC website